Future share price trajectories for clinical-stage biopharmaceutical firms like Outlook Therapeutics depend heavily on regulatory milestones, such as drug application reviews with health authorities like the FDA, clinical trial updates, and capital structure management. Because clinical-stage biotech equities are binary and highly sensitive to regulatory outcomes, share prices experience acute volatility.